ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

HCM HUTCHMED China Limited

18,675
-0,315 (-1,66%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
HUTCHMED China Limited HCM NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
-0,315 -1,66% 18,675 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
18,99 17,46 18,99 18,16 18,99
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
26.4.202414:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05.4.202410:30GLOBEHUTCHMED Highlights Data to be Presented at..
02.4.202406:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
28.3.202401:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
22.3.202401:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05.3.202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.2.202412:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.2.202412:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28.2.202412:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07.2.202412:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.2.202401:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02.2.202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.2.202409:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01.2.202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.2.202409:30GLOBEHUTCHMED to Announce 2023 Final Results
30.1.202412:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.1.202405:53GLOBEHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval..
11.1.202412:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.1.202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
11.1.202401:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
29.12.202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.12.202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.12.202308:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
13.12.202305:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATE®..
13.12.202301:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
07.12.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.12.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.12.202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
01.12.202301:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
30.11.202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.11.202314:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
09.11.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.11.202301:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01.11.202313:35GLOBEInternational companies to host live webcasts at Deutsche..
24.10.202312:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.10.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.10.202310:30GLOBEHUTCHMED Highlights Clinical Data to be Presented at..
29.9.202312:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.9.202310:30GLOBEHUTCHMED Announces Submission of New Drug Application for..
14.9.202312:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202310:30GLOBEHUTCHMED Highlights Presentation of Results from the Phase..
12.9.202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
12.9.202302:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
31.8.202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.8.202312:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.8.202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
29.8.202302:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
21.8.202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock